TB-302 / Boryung Group, Therabest - LARVOL DELTA

Vigencell -Terravest Sign Joint Development Agreement for CAR-NK Cell Therapy [Google translation] (HIT News) - "Vigencell...announced on the 30th that it has signed a joint research and development agreement for the GD2 CAR-NK cell therapy 'TB-302' with Teravest, an iPSC-derived immune cell therapy company...Through this agreement, the two companies will jointly develop an off-the-shelf GD2 CAR-NK cell therapy for intractable solid cancers including glioblastoma. Vigencell plans to introduce TB-302, an iPSC-based CAR-NK therapy from Teravest, and pursue clinical development using it in the future....With this contract, Vigencell will pay a down payment of 3 billion won to Teravest and jointly conduct research and development by introducing TB-302 with the goal of treating intractable solid cancers including glioblastoma."

Licensing / partnership • Glioblastoma • Solid Tumor